Clinical trial phases are the sequential stages of human testing that every investigational drug must pass through to demonstrate safety and efficacy before receiving marketing approval. Each phase answers specific questions about the compound’s behavior in humans, with progressively larger patient populations and more rigorous endpoints. The phase structure provides a logical framework for managing risk: early phases are small and exploratory, while later phases are large and confirmatory.
Phase 0
Phase 0, also called microdosing or exploratory IND studies, is an optional first step that precedes traditional Phase I trials. In a Phase 0 study, a small number of subjects — typically ten to fifteen — receive a single subtherapeutic dose of the investigational drug, usually less than one-hundredth of the projected therapeutic dose. The objective is not to assess safety or efficacy but to gather preliminary pharmacokinetic and pharmacodynamic data using sensitive analytical techniques such as accelerator mass spectrometry or positron emission tomography. Phase 0 studies can accelerate development by providing early evidence that the drug reaches its intended target and behaves as predicted from preclinical models.
Phase I
Phase I is the first administration of the investigational drug to humans, typically conducted in twenty to eighty healthy volunteers. The primary objectives are to evaluate safety, tolerability, and pharmacokinetics. Phase I studies use a dose-escalation design in which cohorts of subjects receive progressively higher doses until predefined stopping criteria — such as the maximum tolerated dose — are reached. Intensive blood sampling characterizes the drug’s absorption, distribution, metabolism, and excretion profile in humans, and safety monitoring captures adverse events, laboratory abnormalities, and vital sign changes. For oncology drugs, Phase I studies may enroll patients rather than healthy volunteers because of the potential toxicity of cytotoxic agents.
Phase II
Phase II studies are the first therapeutic exploratory trials, enrolling one hundred to three hundred patients with the target disease. The primary goal is proof of concept — demonstrating that the drug produces a measurable clinical benefit in the intended patient population. Phase II is often divided into Phase IIa (proof of concept, open-label or single-arm) and Phase IIb (dose-ranging, randomized, controlled). Dose-ranging studies identify the lowest dose that provides meaningful efficacy with acceptable tolerability, establishing the dose for Phase III. Secondary endpoints explore patient subgroups, biomarker responses, and duration of effect. Approximately one-third of drugs that enter Phase II proceed to Phase III.
Phase III
Phase III trials are large, confirmatory studies designed to provide definitive evidence of efficacy and safety. They enroll from several hundred to several thousand patients across multiple sites, often in different countries. Phase III trials are typically randomized, double-blind, and controlled against placebo or an active comparator. The primary endpoint is a clinically meaningful outcome, such as survival, disease progression, or symptom improvement. The sample size is calculated to provide adequate statistical power to detect a predefined treatment effect. Two positive Phase III trials are usually required for regulatory approval. Phase III is the most expensive and time-consuming phase, often lasting two to four years.
Phase IV
Phase IV studies, also called post-marketing surveillance studies, are conducted after regulatory approval and commercial launch. These studies monitor the drug’s long-term safety and effectiveness in real-world clinical settings, often in patient populations that were excluded from pre-approval trials, such as children, the elderly, pregnant women, or patients with comorbidities. Phase IV studies can identify rare adverse events, drug-drug interactions, and unexpected safety signals that were not detected during the pre-approval program. Regulatory authorities may require specific post-marketing studies as a condition of approval, particularly when accelerated or conditional approval pathways were used.
Duration and Subject Numbers
The total development timeline from first-in-human to approval typically spans ten to fifteen years, with approximately six to seven years consumed by clinical trials. Phase I studies last several months; Phase II studies last from six months to two years; and Phase III studies last two to four years. The total number of subjects exposed to the investigational drug before approval ranges from a few hundred for drugs targeting rare diseases to several thousand for chronic condition therapies. Regulatory reviews add six to twelve months after submission, and Phase IV commitments extend surveillance for years after approval.
Regulatory Decision Points
Each phase ends with a go or no-go decision based on predefined criteria. At the end of Phase I, the sponsor decides whether the safety and pharmacokinetic profile support progression to patient studies. At the end of Phase II, the decision focuses on whether the proof-of-concept data justify the investment in expensive Phase III trials. At the end of Phase III, the sponsor submits the marketing application. Regulatory authorities independently evaluate the data at each submission point and may require additional studies before granting approval.
Conclusion
The phased clinical trial system provides a rigorous, stepwise framework for evaluating new medicines in humans. Each phase builds on the knowledge gained in the previous one, progressively reducing uncertainty about the drug’s safety, efficacy, and appropriate use. While the system is demanding, it has proven effective at ensuring that only treatments with a favorable benefit-risk balance reach patients.
